DISCLAIMER
These codes are currently under development by the LOINC team, and are subject to change prior to inclusion in a public release. It is possible that they may not be published in the next, or any, public release. They are provided here for informational purposes only.
SPECIAL USE
Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release.
Guidance for mapping to SARS-CoV-2 LOINC terms
Full list of LOINCs related to SARS-CoV-2/COVID-19
The page linked above includes an option to export terms in CSV format.
Receive email notices of new Special Use LOINC terms
scroll/swipe to view more columns
| Created On | LOINC | Long Common Name | Special Use | Component | Prop | Time | System | Scale | Method | Shortname |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-09-24 | 95826-4 | SARS-CoV-2 (COVID-19) RNA panel - Saliva (oral fluid) by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA panel | - | Pt | Saliva | - | Probe.amp.tar | SARS-CoV-2 RNA Pnl Sal NAA+probe |
| 2020-09-23 | 95825-6 | SARS-CoV-2 (COVID-19) Ab [Presence] in DBS by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab | PrThr | Pt | Bld.dot | Ord | IA | SARS-CoV-2 Ab DBS Ql IA |
| 2020-09-20 | 95823-1 | SARS-related coronavirus E gene [Presence] in Saliva (oral fluid) by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS-related coronavirus E gene | PrThr | Pt | Saliva | Ord | Probe.amp.tar | SARS-rel CoV E gene Sal Ql NAA+probe |
| 2020-09-20 | 95824-9 | SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Saliva (oral fluid) by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 ORF1ab region | PrThr | Pt | Saliva | Ord | Probe.amp.tar | SARS-CoV-2 ORF1ab Sal Ql NAA+probe |
| 2020-09-01 | 95793-6 | Immunization priority tier | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Immunization priority tier | Type | Pt | ^Patient | Nom | Immunization priority tier | |
| 2020-08-25 | 95715-9 | Population group | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Population group | Type | Pt | ^Patient | Nom | Population group | |
| 2020-08-18 | 95608-6 | SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory specimen by NAA with non-probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA | PrThr | Pt | Respiratory | Ord | Non-probe.amp.tar | SARS-CoV-2 RNA Resp Ql NAA+non-probe |
| 2020-08-18 | 95609-4 | SARS-CoV-2 (COVID-19) S gene [Presence] in Respiratory specimen by Sequencing | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 S gene | PrThr | Pt | Respiratory | Ord | Sequencing | SARS-CoV-2 S gene Resp Ql Seq |
| 2020-08-07 | 95542-7 | SARS-CoV-2 (COVID-19) IgG+IgM Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgG+IgM | PrThr | Pt | Ser/Plas/Bld | Ord | IA.rapid | SARS-CoV-2 IgG+IgM SerPlBld Ql IA.rapid |
| 2020-07-26 | 95521-1 | SARS-CoV-2 (COVID-19) N gene [#/volume] (viral load) in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | NCnc | Pt | Respiratory | Qn | Probe.amp.tar | SARS-CoV-2 N gene # Resp NAA+probe |
| 2020-07-26 | 95522-9 | SARS-CoV-2 (COVID-19) N gene [Log #/volume] (viral load) in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | LnCnc | Pt | Respiratory | Qn | Probe.amp.tar | SARS-CoV-2 N gene Resp NAA+probe-Log# |
| 2020-07-13 | 95427-1 | SARS-CoV-2 (COVID-19) IgA Ab [Titer] in Serum or Plasma by Immunofluorescence | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgA | Titr | Pt | Ser/Plas | Qn | IF | SARS-CoV-2 IgA Titr SerPl IF |
| 2020-07-13 | 95428-9 | SARS-CoV-2 (COVID-19) IgM Ab [Titer] in Serum or Plasma by Immunofluorescence | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgM | Titr | Pt | Ser/Plas | Qn | IF | SARS-CoV-2 IgM Titr SerPl IF |
| 2020-07-13 | 95429-7 | SARS-CoV-2 (COVID-19) IgG Ab [Titer] in Serum or Plasma by Immunofluorescence | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgG | Titr | Pt | Ser/Plas | Qn | IF | SARS-CoV-2 IgG Titr SerPl IF |
| 2020-06-26 | 95423-0 | Influenza virus A and B and SARS-CoV-2 (COVID-19) identified in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Influenza virus A & Influenza virus B & SARS coronavirus 2 identified | Prid | Pt | Respiratory | Nom | Probe.amp.tar | FLUABV + SARS-CoV-2 Resp NAA+probe |
| 2020-06-26 | 95422-2 | Influenza virus A and B RNA and SARS-CoV-2 (COVID-19) N gene panel - Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Influenza virus A & B RNA & SARS coronavirus 2 N gene panel | - | Pt | Respiratory | - | Probe.amp.tar | FluAB + SARS-CoV-2 Pnl Resp NAA+prb |
| 2020-06-26 | 95424-8 | SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory specimen by Sequencing | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA | PrThr | Pt | Respiratory | Ord | Sequencing | SARS-CoV-2 RNA Resp Ql Seq |
| 2020-06-26 | 95425-5 | SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | PrThr | Pt | Saliva | Ord | Probe.amp.tar | SARS-CoV-2 N gene Sal Ql NAA+probe |
| 2020-06-23 | 95417-2 | Whether this is the patient's first test for condition of interest | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | First test for condition of interest | Find | Pt | ^Patient | Ord | First test for condition of interest | |
| 2020-06-23 | 95418-0 | Whether patient is employed in a healthcare setting | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Employed in a healthcare setting | Find | Pt | ^Patient | Ord | Employed in healthcare setting | |
| 2020-06-23 | 95419-8 | Whether the patient has symptoms related to condition of interest | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Has symptoms related to condition of interest | Find | Pt | ^Patient | Ord | Has symptoms for condition | |
| 2020-06-23 | 95420-6 | Whether the patient was admitted to intensive care unit (ICU) for condition of interest | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Admitted to intensive care unit for condition of interest | Find | Pt | ^Patient | Ord | Admitted to ICU for condition | |
| 2020-06-23 | 95421-4 | Whether patient resides in a congregate care setting | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Resides in a congregate care setting | Find | Pt | ^Patient | Ord | Resides in a congregate care setting | |
| 2020-05-29 | 95380-2 | Influenza virus A and B and SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Influenza virus A & Influenza virus B & SARS coronavirus 2 & SARS-related coronavirus RNA panel | - | Pt | Respiratory | - | Probe.amp.tar | FluAB+SARS-CoV-2+SARSr-CoV Resp NAA+prb |
| 2020-09-15 | 95818-1 | Pulmonary artery Mean blood pressure--during anesthesia | Intravascular mean^during anesthesia | Pres | Pt | Pulmonary artery | Qn | PA BP mean--during anesthesia | ||
| 2020-09-15 | 95819-9 | Pulmonary artery Diastolic blood pressure--during anesthesia | Intravascular diastolic^during anesthesia | Pres | Pt | Pulmonary artery | Qn | PA BP dias--during anesthesia | ||
| 2020-09-15 | 95820-7 | Pulmonary artery Systolic blood pressure--during anesthesia | Intravascular systolic^during anesthesia | Pres | Pt | Pulmonary artery | Qn | PA BP sys--during anesthesia | ||
| 2020-09-15 | 95821-5 | Mean blood pressure by Noninvasive--during anesthesia | Intravascular mean^during anesthesia | Pres | Pt | Arterial system | Qn | Noninvasive | BP mean by Noninv--during anesthesia | |
| 2020-09-15 | 95822-3 | Mean blood pressure--during anesthesia | Intravascular mean^during anesthesia | Pres | Pt | Arterial system | Qn | BP mean--during anesthesia | ||
| 2020-09-14 | 95817-3 | Oxygen/Gas total 24 hour maximum Inhaled gas | Oxygen/Gas.total | VFr | 24H^max | Inhl gas | Qn | FIO2 24h Max | ||
| 2020-09-11 | 95809-0 | Carbapenem resistance genes [Presence] by Molecular method | Carbapenem resistance genes | PrThr | Pt | Isolate/Specimen | Ord | Molgen | CPR genes Islt/Spm Ql | |
| 2020-09-08 | 95800-9 | Immunoglobulin light chains.free panel - Urine | Immunoglobulin light chains.free panel | - | - | Urine | - | Immunoglobulin LC free Pnl Ur | ||
| 2020-09-08 | 95801-7 | Immunoglobulin light chains.free and IFE panel - Urine | Immunoglobulin light chains.free & immunofixation panel | - | - | Urine | - | Immunoglobulin LC free + IFE Pnl Ur | ||
| 2020-09-08 | 95802-5 | Breastfeeding Progress note | Progress note | Find | Pt | {Setting} | Doc | Breastfeeding | Breastfeeding Progress note | |
| 2020-09-08 | 95803-3 | Breastfeeding Note | Note | Find | Pt | {Setting} | Doc | Breastfeeding | Breastfeeding Note | |
| 2020-09-08 | 95804-1 | Breastfeeding Telehealth Note | Note | Find | Pt | Telehealth | Doc | Breastfeeding | Breastfeeding Telehealth Note | |
| 2020-09-08 | 95805-8 | Breastfeeding Evaluation note | Evaluation note | Find | Pt | {Setting} | Doc | Breastfeeding | Breastfeeding Eval note | |
| 2020-09-08 | 95806-6 | Breastfeeding Consult note | Consultation note | Find | Pt | {Setting} | Doc | Breastfeeding | Breastfeeding Consult note | |
| 2020-09-08 | 95807-4 | Chylomicrons [Presence] in Urine | Chylomicrons | PrThr | Pt | Urine | Ord | Chylo Ur Ql | ||
| 2020-09-08 | 95808-2 | Cholesterol and triglyceride and chylomicrons panel - Urine | Cholesterol & triglyceride & chylomicrons panel | - | Pt | Urine | - | Cholest+triglyceride+chylomicrons Pnl Ur | ||
| 2020-09-02 | 95794-4 | Adrenal insufficiency emergency action plan | Adrenal insufficiency emergency action plan | Find | Pt | {Setting} | Doc | {Role} | Adrenal insufficiency action plan | |
| 2020-09-02 | 95795-1 | HBG1 and HBG2 genes full mutation analysis in Blood or Tissue by Sequencing | HBG1 gene & HBG2 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | HBG1 + HBG2 Full Mut Anl Bld/T Seq | |
| 2020-09-02 | 95796-9 | Opioids panel - Urine by Screen method | Opioids panel | - | Pt | Urine | - | Screen | Opioids Pnl Ur Scn | |
| 2020-09-02 | 95798-5 | Normeperidine [Presence] in Urine by Screen method | Normeperidine | PrThr | Pt | Urine | Ord | Screen | Normeperidine Ur Ql Scn | |
| 2020-09-02 | 95797-7 | Norfentanyl [Presence] in Urine by Screen method | Norfentanyl | PrThr | Pt | Urine | Ord | Screen | Norfentanyl Ur Ql Scn | |
| 2020-09-02 | 95799-3 | O-nortramadol [Presence] in Urine by Screen method | O-nortramadol | PrThr | Pt | Urine | Ord | Screen | O-nortramadol Ur Ql Scn | |
| 2020-08-31 | 95787-8 | Adrenal cortical carcinoma probability [Likelihood] based on clinical data | Adrenal cortical carcinoma probability | Likelihood | Pt | ^Patient | Qn | Based on clinical data | ACC Prob from clin data | |
| 2020-08-31 | 95788-6 | Adrenal malignancy other than ACC probability [Likelihood] based on clinical data | Adrenal malignancy other than adrenal cortical carcinoma probability | Likelihood | Pt | ^Patient | Qn | Based on clinical data | Other adrenal malig Prob from clin data | |
| 2020-08-31 | 95789-4 | Benign mass probability [Likelihood] based on clinical data | Benign mass probability | Likelihood | Pt | ^Patient | Qn | Based on clinical data | Benign mass Prob from clin data | |
| 2020-08-31 | 95790-2 | Adrenal cortical carcinoma probability [Likelihood] based on clinical and lab data | Adrenal cortical carcinoma probability | Likelihood | Pt | ^Patient | Qn | Based on clinical+lab data | ACC Prob from clin+lab data | |
| 2020-08-31 | 95791-0 | Adrenal malignancy other than ACC probability [Likelihood] based on clinical and lab data | Adrenal malignancy other than adrenal cortical carcinoma probability | Likelihood | Pt | ^Patient | Qn | Based on clinical+lab data | Other adrenal malig Prob clin+lab data | |
| 2020-08-31 | 95792-8 | Benign mass probability [Likelihood] based on clinical and lab data | Benign mass probability | Likelihood | Pt | ^Patient | Qn | Based on clinical+lab data | Benign mass Prob from clin+lab data | |
| 2020-08-27 | 95746-4 | Immunology Progress note | Progress note | Find | Pt | {Setting} | Doc | Immunology | Immunology Progress note | |
| 2020-08-27 | 95747-2 | Immunology Referral note | Referral note | Find | Pt | {Setting} | Doc | Immunology | Immunology Referral note | |
| 2020-08-27 | 95748-0 | Immunology Education note | Education note | Find | Pt | {Setting} | Doc | Immunology | Immunology Educ note | |
| 2020-08-27 | 95749-8 | Immunology Initial evaluation note | Initial evaluation note | Find | Pt | {Setting} | Doc | Immunology | Immunology Initial eval note | |
| 2020-08-27 | 95750-6 | Immunology procedure note | Procedure note | Find | Pt | {Setting} | Doc | Immunology | Immunology Procedure note | |
| 2020-08-27 | 95751-4 | Immunology Flowsheet | Flowsheet | Find | Pt | {Setting} | Doc | Immunology | Immunology Flowsheet | |
| 2020-08-27 | 95753-0 | Immunology Evaluation note | Evaluation note | Find | Pt | {Setting} | Doc | Immunology | Immunology Eval note | |
| 2020-08-27 | 95752-2 | Immunology Plan of care note | Plan of care note | Find | Pt | {Setting} | Doc | Immunology | Immunology Plan of care note | |
| 2020-08-27 | 95754-8 | Allergy Referral note | Referral note | Find | Pt | {Setting} | Doc | Allergy | Allergy Referral note | |
| 2020-08-27 | 95755-5 | Allergy Initial evaluation note | Initial evaluation note | Find | Pt | {Setting} | Doc | Allergy | Allergy Initial eval note | |
| 2020-08-27 | 95756-3 | Allergy procedure note | Procedure note | Find | Pt | {Setting} | Doc | Allergy | Allergy Procedure note | |
| 2020-08-27 | 95757-1 | Allergy Progress note | Progress note | Find | Pt | {Setting} | Doc | Allergy | Allergy Progress note | |
| 2020-08-27 | 95758-9 | Allergy Flowsheet | Flowsheet | Find | Pt | {Setting} | Doc | Allergy | Allergy Flowsheet | |
| 2020-08-27 | 95759-7 | Allergy Plan of care note | Plan of care note | Find | Pt | {Setting} | Doc | Allergy | Allergy Plan of care note | |
| 2020-08-27 | 95760-5 | Allergy Education note | Education note | Find | Pt | {Setting} | Doc | Allergy | Allergy Educ note | |
| 2020-08-27 | 95761-3 | Allergy Consult note | Consultation note | Find | Pt | {Setting} | Doc | Allergy | Allergy Consult note | |
| 2020-08-27 | 95762-1 | Allergy Diagnostic study note | Diagnostic study note | Find | Pt | {Setting} | Doc | Allergy | Allergy Diag study note | |
| 2020-08-27 | 95763-9 | Allergy Evaluation note | Evaluation note | Find | Pt | {Setting} | Doc | Allergy | Allergy Eval note | |
| 2020-08-27 | 95765-4 | Candida auris DNA [Presence] in Unspecified specimen by NAA with non-probe detection | Candida auris DNA | PrThr | Pt | XXX | Ord | Non-probe.amp.tar | C auris DNA XXX Ql NAA+non-probe | |
| 2020-08-27 | 95764-7 | Candida auris DNA [Presence] in Urine by NAA with non-probe detection | Candida auris DNA | PrThr | Pt | Urine | Ord | Non-probe.amp.tar | C auris DNA Ur Ql NAA+non-probe | |
| 2020-08-27 | 95766-2 | Candida auris DNA [Presence] in Blood by NAA with non-probe detection | Candida auris DNA | PrThr | Pt | Bld | Ord | Non-probe.amp.tar | C auris DNA Bld Ql NAA+non-probe | |
| 2020-08-27 | 95767-0 | Cefiderocol [Susceptibility] by Disk diffusion (KB) | Cefiderocol | Susc | Pt | Isolate | OrdQn | Agar diffusion | Cefiderocol Islt KB | |
| 2020-08-27 | 95768-8 | Parathyrin.1-84 [Moles/volume] in Serum or Plasma by Immunoassay | Parathyrin.1-84 | SCnc | Pt | Ser/Plas | Qn | IA | Parathyrin.1-84 SerPl IA-sCnc | |
| 2020-08-27 | 95769-6 | BMPR1A gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | BMPR1A gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | BMPR1A Del+Dup + Full Mut Anl Bld/T | |
| 2020-08-27 | 95770-4 | GALT gene targeted mutation analysis in Blood or Tissue by Molecular genetics method | GALT gene targeted mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | GALT gene Mut Anl Bld/T | |
| 2020-08-27 | 95771-2 | GATA2 gene full mutation analysis in Blood or Tissue by Sequencing | GATA2 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | GATA2 gene Full Mut Anl Bld/T Seq | |
| 2020-08-27 | 95772-0 | IDH1 and IDH2 genes targeted mutation analysis in Blood or Tissue by Molecular genetics method | IDH1 gene & IDH2 gene targeted mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | IDH1 + IDH2 Mut Anl Bld/T | |
| 2020-08-27 | 95773-8 | ACADM gene full mutation analysis in Blood or Tissue by Sequencing | ACADM gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | ACADM gene Full Mut Anl Bld/T Seq | |
| 2020-08-27 | 95774-6 | MSH6 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | MSH6 gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | MSH6 gene Del+Dup + Full Mut Anl Bld/T | |
| 2020-08-27 | 95775-3 | HGSNAT gene full mutation analysis in Blood or Tissue by Sequencing | HGSNAT gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | HGSNAT Full Mut Anl Bld/T Seq | |
| 2020-08-27 | 95776-1 | GNS gene full mutation analysis in Blood or Tissue by Sequencing | GNS gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | GNS Full Mut Anl Bld/T Seq | |
| 2020-08-27 | 95777-9 | ACADS gene full mutation analysis in Blood or Tissue by Sequencing | ACADS gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | ACADS gene Full Mut Anl Bld/T Seq | |
| 2020-08-27 | 95778-7 | TERT gene promotor region targeted mutation analysis in Tissue by Molecular genetics method | TERT gene promotor region targeted mutation analysis | Find | Pt | Tiss | Doc | Molgen | TERT promotor region Mut Anl Tiss | |
| 2020-08-27 | 95779-5 | TFE3 gene rearrangements in Tissue by FISH | TFE3 gene rearrangements | Find | Pt | Tiss | Doc | FISH | TFE3 rearrange Tiss FISH | |
| 2020-08-27 | 95780-3 | TFEB gene rearrangements in Tissue by FISH | TFEB gene rearrangements | Find | Pt | Tiss | Doc | FISH | TFEB rearrange Tiss FISH | |
| 2020-08-27 | 95781-1 | ATP7B gene full mutation analysis in Blood or Tissue by Sequencing | ATP7B gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | ATP7B gene Full Mut Anl Bld/T Seq | |
| 2020-08-27 | 95782-9 | ABCD1 gene full mutation analysis in Blood or Tissue by Sequencing | ABCD1 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | ABCD1 gene Full Mut Anl Bld/T Seq | |
| 2020-08-27 | 95783-7 | ETV6 gene rearrangements in Blood or Marrow by FISH | ETV6 gene rearrangements | Find | Pt | Bld/Bone mar | Doc | FISH | ETV6 rearrange Bld/Mar FISH | |
| 2020-08-27 | 95785-2 | FOXL2 gene targeted mutation analysis in Tissue by Molecular genetics method | FOXL2 gene targeted mutation analysis | Find | Pt | Tiss | Doc | Molgen | FOXL2 Mut Anl Tiss | |
| 2020-08-27 | 95786-0 | Gene XXX mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method | Gene XXX mutation analysis limited to known familial mutations | Find | Pt | Bld/Tiss | Doc | Molgen | Gene XXX Fam Mut Anl Bld/T | |
| 2020-08-27 | 95784-5 | FGFR2 gene rearrangements in Tissue by FISH | FGFR2 gene rearrangements | Find | Pt | Tiss | Doc | FISH | FGFR2 rearrange Tiss FISH | |
| 2020-08-26 | 95727-4 | Contact Name | Name | Pn | Pt | ^Contact | Nom | Contact Name | ||
| 2020-08-26 | 95728-2 | Contact Address | Address | Addr | Pt | ^Contact | Nom | Contact Address | ||
| 2020-08-26 | 95729-0 | Relationship to decedent Contact | Relationship to decedent | Type | Pt | ^Contact | Nom | Rel to decedent Contact | ||
| 2020-08-26 | 95730-8 | Surviving spouse name | Surviving spouse name | Pn | Pt | ^Patient | Nom | Surviving spouse name | ||
| 2020-08-26 | 95731-6 | Mother's Maiden name | Maiden name | Pn | Pt | ^Mother | Nom | Mother's Maiden name | ||
| 2020-08-25 | 95620-1 | Neonatal pain, agitation, and sedation scale panel NPASS | Neonatal pain, agitation, & sedation scale panel | - | Pt | ^Patient | - | NPASS | NPASS pnl | |
| 2020-08-25 | 95622-7 | Pain/agitation.crying or irritability NPASS | Pain &or agitation.crying or irritability | Find | Pt | ^Patient | Ord | NPASS | Pain/agit cry irritab NPASS | |
| 2020-08-25 | 95623-5 | Pain/agitation.behavior state NPASS | Pain &or agitation.behavior state | Find | Pt | ^Patient | Ord | NPASS | Pain/agit behav NPASS | |
| 2020-08-25 | 95621-9 | Pain/agitation panel NPASS | Pain &or agitation panel | - | Pt | ^Patient | - | NPASS | Pain/agitat pnl NPASS | |
| 2020-08-25 | 95625-0 | Pain/agitation.extremities tone NPASS | Pain &or agitation.extremities tone | Find | Pt | ^Patient | Ord | NPASS | Pain/agi extrem tone NPASS | |
| 2020-08-25 | 95626-8 | Pain/agitation.vital signs variability NPASS | Pain &or agitation.vital signs variability | Find | Pt | ^Patient | Ord | NPASS | Pain/agi vital sign var NPASS | |
| 2020-08-25 | 95624-3 | Pain/agitation.facial expression NPASS | Pain &or agitation.facial expression | Find | Pt | ^Patient | Ord | NPASS | Pain/agit face exp NPASS | |
| 2020-08-25 | 95627-6 | Pain agitation total score NPASS | Pain &or agitation total score | Score | Pt | ^Patient | Qn | NPASS | Pain agi tot score NPASS | |
| 2020-08-25 | 95628-4 | Pain/agitation level NPASS | Pain &or agitation level | Find | Pt | ^Patient | Ord | NPASS | Pain/agi level NPASS | |
| 2020-08-25 | 95630-0 | Sedation.crying or irritability NPASS | Sedation.crying or irritability | Find | Pt | ^Patient | Ord | NPASS | Sedate cry irritab NPASS | |
| 2020-08-25 | 95631-8 | Sedation.behavior state NPASS | Sedation.behavior state | Find | Pt | ^Patient | Ord | NPASS | Sed.behav state NPASS | |
| 2020-08-25 | 95629-2 | Sedation panel NPASS | Sedation panel | - | Pt | ^Patient | - | NPASS | Sed pnl NPASS | |
| 2020-08-25 | 95634-2 | Sedation.vital signs variability NPASS | Sedation.vital signs variability | Find | Pt | ^Patient | Ord | NPASS | Sed.vital signs NPASS | |
| 2020-08-25 | 95632-6 | Sedation.facial expression NPASS | Sedation.facial expression | Find | Pt | ^Patient | Ord | NPASS | Sed.facial exp NPASS | |
| 2020-08-25 | 95633-4 | Sedation.extremities tone NPASS | Sedation.extremities tone | Find | Pt | ^Patient | Ord | NPASS | Sed.extrem tone NPASS | |
| 2020-08-25 | 95636-7 | Sedation level NPASS | Sedation level | Find | Pt | ^Patient | Ord | NPASS | Sed lvl NPASS | |
| 2020-08-25 | 95635-9 | Sedation total score NPASS | Sedation total score | Score | Pt | ^Patient | Qn | NPASS | Sed total score NPASS | |
| 2020-08-25 | 95637-5 | Jamestown canyon virus Ab [Titer] in Unspecified specimen by Neutralization test | Jamestown Canyon virus Ab | Titr | Pt | XXX | Qn | Neut | JCV Ab Titr XXX Nt | |
| 2020-08-25 | 95638-3 | California encephalitis virus Ab [Titer] in Unspecified specimen by Neutralization test | California encephalitis virus Ab | Titr | Pt | XXX | Qn | Neut | CEV Ab Titr XXX Nt | |
| 2020-08-25 | 95639-1 | Cache valley virus Ab [Titer] in Unspecified specimen by Neutralization test | Cache Valley virus Ab | Titr | Pt | XXX | Qn | Neut | CVV Ab Titr XXX Nt | |
| 2020-08-25 | 95640-9 | Colorado tick fever virus Ab [Titer] in Unspecified specimen by Neutralization test | Colorado tick fever virus Ab | Titr | Pt | XXX | Qn | Neut | CTFV Ab Titr XXX Nt | |
| 2020-08-25 | 95641-7 | Barmah forest virus Ab [Titer] in Unspecified specimen by Neutralization test | Barmah Forest virus Ab | Titr | Pt | XXX | Qn | Neut | BFV Ab Titr XXX Nt | |
| 2020-08-25 | 95642-5 | Snowshoe hare virus Ab [Titer] in Unspecified specimen by Neutralization test | Snowshoe hare virus Ab | Titr | Pt | XXX | Qn | Neut | SSHV Ab Titr XXX Nt | |
| 2020-08-25 | 95643-3 | Tahyna virus Ab [Titer] in Unspecified specimen by Neutralization test | Tahyna virus Ab | Titr | Pt | XXX | Qn | Neut | TAHV Ab Titr XXX Nt | |
| 2020-08-25 | 95644-1 | Japanese encephalitis virus Ab [Titer] in Unspecified specimen by Neutralization test | Japanese encephalitis virus Ab | Titr | Pt | XXX | Qn | Neut | JEV Ab Titr XXX Nt | |
| 2020-08-25 | 95645-8 | Murray Valley encephalitis virus Ab [Titer] in Unspecified specimen by Neutralization test | Murray Valley encephalitis virus Ab | Titr | Pt | XXX | Qn | Neut | MVEV Ab Titr XXX Nt | |
| 2020-08-25 | 95646-6 | Ross River virus Ab [Titer] in Unspecified specimen by Neutralization test | Ross River virus Ab | Titr | Pt | XXX | Qn | Neut | RRV Ab Titr XXX Nt | |
| 2020-08-25 | 95647-4 | Powassan virus Ab [Titer] in Unspecified specimen by Neutralization test | Powassan virus Ab | Titr | Pt | XXX | Qn | Neut | POWV Ab Titr XXX Nt | |
| 2020-08-25 | 95648-2 | Sindbis virus Ab [Titer] in Unspecified specimen by Neutralization test | Sindbis virus Ab | Titr | Pt | XXX | Qn | Neut | SINV Ab Titr XXX Nt | |
| 2020-08-25 | 95649-0 | Chikungunya virus Ab [Titer] in Unspecified specimen by Neutralization test | Chikungunya virus Ab | Titr | Pt | XXX | Qn | Neut | CHIKV Ab Titr XXX Nt | |
| 2020-08-25 | 95650-8 | Mayaro virus Ab [Titer] in Unspecified specimen by Neutralization test | Mayaro virus Ab | Titr | Pt | XXX | Qn | Neut | MAYV Ab Titr XXX Nt | |
| 2020-08-25 | 95651-6 | Yellow fever virus Ab [Titer] in Unspecified specimen by Neutralization test | Yellow Fever virus Ab | Titr | Pt | XXX | Qn | Neut | YFV Ab Titr XXX Nt | |
| 2020-08-25 | 95652-4 | Venezuelan equine encephalitis virus Ab [Titer] in Unspecified specimen by Neutralization test | Venezuelan equine encephalitis virus Ab | Titr | Pt | XXX | Qn | Neut | VEEV Ab Titr XXX Nt | |
| 2020-08-25 | 95653-2 | La Crosse virus Ab [Titer] in Unspecified specimen by Neutralization test | La Crosse virus Ab | Titr | Pt | XXX | Qn | Neut | LACV Ab Titr XXX Nt | |
| 2020-08-25 | 95654-0 | Eastern equine encephalitis virus Ab [Titer] in Unspecified specimen by Neutralization test | Eastern equine encephalitis virus Ab | Titr | Pt | XXX | Qn | Neut | EEEV Ab Titr XXX Nt | |
| 2020-08-25 | 95655-7 | Western equine encephalitis virus Ab [Titer] in Unspecified specimen by Neutralization test | Western equine encephalitis virus Ab | Titr | Pt | XXX | Qn | Neut | WEEV Ab Titr XXX Nt | |
| 2020-08-25 | 95657-3 | Flavivirus identified in Unspecified specimen by Neutralization test | Flavivirus identified | Prid | Pt | XXX | Nom | Neut | Flavivirus XXX Nt | |
| 2020-08-25 | 95658-1 | Influenza virus A H7 Eurasia RNA [Presence] in Unspecified specimen by NAA with probe detection | Influenza virus A H7 Eurasia RNA | PrThr | Pt | XXX | Ord | Probe.amp.tar | FLUAV H7 Euras RNA XXX Ql NAA+probe | |
| 2020-08-25 | 95660-7 | Eastern equine encephalitis virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Eastern equine encephalitis virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | EEEV IgM XXX Ql IA | |
| 2020-08-25 | 95659-9 | Adenovirus RNA [Presence] in Unspecified specimen by NAA with probe detection | Adenovirus RNA | PrThr | Pt | XXX | Ord | Probe.amp.tar | HAdV RNA XXX Ql NAA+probe | |
| 2020-08-25 | 95661-5 | Barmah forest virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Barmah Forest virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | BFV IgG XXX Ql IA | |
| 2020-08-25 | 95662-3 | Japanese encephalitis virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Japanese encephalitis virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | JEV IgA XXX Ql IA | |
| 2020-08-25 | 95663-1 | Zika virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Zika virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | ZIKV IgG XXX Ql IA | |
| 2020-08-25 | 95664-9 | Jamestown canyon virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Jamestown Canyon virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | JCV IgG XXX Ql IA | |
| 2020-08-25 | 95665-6 | Snowshoe hare virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Snowshoe hare virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | SSHV IgG XXX Ql IA | |
| 2020-08-25 | 95666-4 | Tahyna virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Tahyna virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | TAHV IgG XXX Ql IA | |
| 2020-08-25 | 95667-2 | Japanese encephalitis virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Japanese encephalitis virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | JEV IgG XXX Ql IA | |
| 2020-08-25 | 95668-0 | Highlands J virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Highlands J virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | HJV IgG XXX Ql IA | |
| 2020-08-25 | 95669-8 | Murray Valley encephalitis virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Murray Valley encephalitis virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | MVEV IgG XXX Ql IA | |
| 2020-08-25 | 95670-6 | Ross River virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Ross River virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | RRV IgG XXX Ql IA | |
| 2020-08-25 | 95671-4 | Sindbis virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Sindbis virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | SINV IgG XXX Ql IA | |
| 2020-08-25 | 95672-2 | Chikungunya virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Chikungunya virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | CHIKV IgG XXX Ql IA | |
| 2020-08-25 | 95673-0 | Dengue virus 1+2+3+4 IgG Ab [Presence] in Unspecified specimen by Immunoassay | Dengue virus 1+2+3+4 Ab.IgG | PrThr | Pt | XXX | Ord | IA | DENV1+2+3+4 IgG XXX Ql IA | |
| 2020-08-25 | 95674-8 | Mayaro virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Mayaro virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | MAYV IgG XXX Ql IA | |
| 2020-08-25 | 95675-5 | Yellow fever virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Yellow Fever virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | YFV IgG XXX Ql IA | |
| 2020-08-25 | 95676-3 | Venezuelan equine encephalitis virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Venezuelan equine encephalitis virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | VEEV IgG XXX Ql IA | |
| 2020-08-25 | 95677-1 | Saint Louis encephalitis virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Saint Louis encephalitis virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | SLEV IgG XXX Ql IA | |
| 2020-08-25 | 95678-9 | Western equine encephalitis virus IgG Ab [Presence] in Unspecified specimen by Immunoassay | Western equine encephalitis virus Ab.IgG | PrThr | Pt | XXX | Ord | IA | WEEV IgG XXX Ql IA | |
| 2020-08-25 | 95679-7 | Barmah forest virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Barmah Forest virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | BFV IgM XXX Ql IA | |
| 2020-08-25 | 95681-3 | Tahyna virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Tahyna virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | TAHV IgM XXX Ql IA | |
| 2020-08-25 | 95682-1 | Japanese encephalitis virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Japanese encephalitis virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | JEV IgM XXX Ql IA | |
| 2020-08-25 | 95680-5 | Snowshoe hare virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Snowshoe hare virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | SSHV IgM XXX Ql IA | |
| 2020-08-25 | 95683-9 | Highlands J virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Highlands J virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | HJV IgM XXX Ql IA | |
| 2020-08-25 | 95684-7 | Murray Valley encephalitis virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Murray Valley encephalitis virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | MVEV IgM XXX Ql IA | |
| 2020-08-25 | 95685-4 | Ross River virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Ross River virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | RRV IgM XXX Ql IA | |
| 2020-08-25 | 95686-2 | Sindbis virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Sindbis virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | SINV IgM XXX Ql IA | |
| 2020-08-25 | 95687-0 | Chikungunya virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Chikungunya virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | CHIKV IgM XXX Ql IA | |
| 2020-08-25 | 95688-8 | Dengue virus 1+2+3+4 IgM Ab [Presence] in Unspecified specimen by Immunoassay | Dengue virus 1+2+3+4 Ab.IgM | PrThr | Pt | XXX | Ord | IA | DENV1+2+3+4 IgM XXX Ql IA | |
| 2020-08-25 | 95689-6 | Mayaro virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Mayaro virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | MAYV IgM XXX Ql IA | |
| 2020-08-25 | 95690-4 | Yellow fever virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Yellow Fever virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | YFV IgM XXX Ql IA | |
| 2020-08-25 | 95692-0 | Saint Louis encephalitis virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Saint Louis encephalitis virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | SLEV IgM XXX Ql IA | |
| 2020-08-25 | 95693-8 | Western equine encephalitis virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Western equine encephalitis virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | WEEV IgM XXX Ql IA | |
| 2020-08-25 | 95691-2 | Venezuelan equine encephalitis virus IgM Ab [Presence] in Unspecified specimen by Immunoassay | Venezuelan equine encephalitis virus Ab.IgM | PrThr | Pt | XXX | Ord | IA | VEEV IgM XXX Ql IA | |
| 2020-08-25 | 95695-3 | Colorado tick fever virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Colorado tick fever virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | CTFV IgA XXX Ql IA | |
| 2020-08-25 | 95694-6 | Cache valley virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Cache valley virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | CVV IgA XXX Ql IA | |
| 2020-08-25 | 95696-1 | Barmah forest virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Barmah Forest virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | BFV IgA XXX Ql IA | |
| 2020-08-25 | 95697-9 | Snowshoe hare virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Snowshoe hare virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | SSHV IgA XXX Ql IA | |
| 2020-08-25 | 95698-7 | Tahyna virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Tahyna virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | TAHV IgA XXX Ql IA | |
| 2020-08-25 | 95699-5 | Highlands J virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Highlands J virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | HJV IgA XXX Ql IA | |
| 2020-08-25 | 95700-1 | Murray Valley encephalitis virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Murray Valley encephalitis virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | MVEV IgA XXX Ql IA | |
| 2020-08-25 | 95701-9 | Ross River virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Ross River virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | RRV IgA XXX Ql IA | |
| 2020-08-25 | 95703-5 | West Nile virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | West Nile virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | WNV IgA XXX Ql IA | |
| 2020-08-25 | 95702-7 | Powassan virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Powassan virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | POWV IgA XXX Ql IA | |
| 2020-08-25 | 95706-8 | Dengue virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Dengue virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | DENV IgA XXX Ql IA | |
| 2020-08-25 | 95705-0 | Chikungunya virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Chikungunya virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | CHIKV IgA XXX Ql IA | |
| 2020-08-25 | 95704-3 | Sindbis virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Sindbis virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | SINV IgA XXX Ql IA | |
| 2020-08-25 | 95707-6 | Mayaro virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Mayaro virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | MAYV IgA XXX Ql IA | |
| 2020-08-25 | 95708-4 | Yellow fever virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Yellow Fever virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | YFV IgA XXX Ql IA | |
| 2020-08-25 | 95709-2 | Venezuelan equine encephalitis virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Venezuelan equine encephalitis virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | VEEV IgA XXX Ql IA | |
| 2020-08-25 | 95710-0 | La Crosse virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | La Crosse virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | LACV IgA XXX Ql IA | |
| 2020-08-25 | 95711-8 | Saint Louis encephalitis virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Saint Louis encephalitis virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | SLEV IgA XXX Ql IA | |
| 2020-08-25 | 95712-6 | Eastern equine encephalitis virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Eastern equine encephalitis virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | EEEV IgA XXX Ql IA | |
| 2020-08-25 | 95713-4 | Western equine encephalitis virus IgA Ab [Presence] in Unspecified specimen by Immunoassay | Western equine encephalitis virus Ab.IgA | PrThr | Pt | XXX | Ord | IA | WEEV IgA XXX Ql IA | |
| 2020-08-25 | 95714-2 | Varicella zoster virus IgG Ab [Units/volume] in Unspecified specimen by Immunoassay | Varicella zoster virus Ab.IgG | ACnc | Pt | XXX | Qn | IA | VZV IgG XXX IA-aCnc | |
| 2020-08-24 | 95613-6 | Unpaid caregiver relationship | Unpaid caregiver relationship | Find | Pt | ^Patient | Nom | Unpaid care relation | ||
| 2020-08-24 | 95614-4 | Total score [HITS] | Total score | Score | Pt | ^Patient | Qn | HITS | ||
| 2020-08-24 | 95615-1 | Scream or curse at you [HITS] | Scream or curse at you | Find | 12Mo | ^Patient | Ord | HITS | ||
| 2020-08-24 | 95616-9 | Threaten you with physical harm [HITS] | Threaten you with physical harm | Find | 12Mo | ^Patient | Ord | HITS | ||
| 2020-08-24 | 95617-7 | Insult you or talk down to you [HITS] | Insult you or talk down to you | Find | 12Mo | ^Patient | Ord | HITS | ||
| 2020-08-24 | 95618-5 | Physically hurt you [HITS] | Physically hurt you | Find | 12Mo | ^Patient | Ord | HITS | ||
| 2020-08-24 | 95619-3 | Hurts, insults, threatens, and screams [HITS] | Hurts, insults, threatens, and screams | - | 12Mo | ^Patient | - | HITS | ||
| 2020-08-20 | 95610-2 | XR Teeth Complete Views | Views complete | Find | Pt | Head>Teeth | Doc | XR | XR Teeth Views complete | |
| 2020-08-20 | 95612-8 | Portable XR Unspecified body region Views | Views | Find | Pt | XXX | Doc | XR.portable | XR port Views | |
| 2020-08-20 | 95611-0 | XR Teeth Occlusal Views | Views occlusal | Find | Pt | Head>Teeth | Doc | XR | XR Teeth Occlusal | |
| 2020-08-12 | 95592-2 | Cardiac surgery Outpatient Note | Note | Find | Pt | Outpatient | Doc | Cardiac surgery | Cardiac surgery OP Note | |
| 2020-08-12 | 95606-0 | Stress level - 0-10 numeric rating [Score] 24 hour maximum | Stress level - 0-10 numeric rating | Score | 24H^max | ^Patient | Qn | Stress level 0-10 24h Max Score | ||
| 2020-08-12 | 95607-8 | Sleep quality - 1-5 numeric rating [Score] 24 hour | Sleep quality - 1-5 numeric rating | Score | 24H | ^Patient | Qn | Sleep quality 1-5 rating 24h | ||
| 2020-08-10 | 95543-5 | Aspergillus terreus IgG Ab [Presence] in Serum | Aspergillus terreus Ab.IgG | PrThr | Pt | Ser | Ord | A terreus IgG Ql | ||
| 2020-08-10 | 95544-3 | HTLV I DNA [#/volume] in Unspecified specimen by NAA with probe detection | HTLV I DNA | NCnc | Pt | XXX | Qn | Probe.amp.tar | HTLV I DNA # XXX NAA+probe | |
| 2020-08-10 | 95545-0 | Loprazolam [Mass/volume] in Serum by Confirmatory method | Loprazolam | MCnc | Pt | Ser | Qn | Confirm | Loprazolam Ser Cfm-mCnc | |
| 2020-08-10 | 95546-8 | Diabetes 8Y risk [Likelihood] Calculation | Diabetes 8Y risk | Likelihood | Pt | ^Patient | Qn | Calculation | Diabetes 8Y risk Calcn | |
| 2020-08-10 | 95548-4 | Cardiovascular disease 10Y risk goal based on ACC-AHA Pooled Cohort by Goff 2013 | Cardiovascular disease 10Y risk goal | Likelihood | Pt | ^Patient | Qn | ACC-AHA Pooled Cohort.Goff 2013 | CVD 10Y risk goal ACC-AHA.Goff 2013 | |
| 2020-08-10 | 95547-6 | Patient is being treated for high blood pressure | Patient is being treated for high blood pressure | Find | Pt | ^Patient | Ord | Patient treated for high BP | ||
| 2020-08-10 | 95549-2 | Cardiovascular disease lifetime risk [Likelihood] ACC-AHA Pooled Cohort by Goff 2013 | Cardiovascular disease lifetime risk | Likelihood | Pt | ^Patient | Qn | ACC-AHA Pooled Cohort.Goff 2013 | CVD Lifetime risk ACC-AHA.Goff 2013 | |
| 2020-08-10 | 95550-0 | ABL1 gene c.944C>T [Presence] in Blood or Marrow by Molecular genetics method | ABL1 gene.c.944C>T | PrThr | Pt | Bld/Bone mar | Ord | Molgen | ABL1 c.944C>T Bld/Mar Ql | |
| 2020-08-10 | 95552-6 | 4p16.3 chromosome deletion in Blood or Tissue by FISH | 4p16.3 chromosome deletion | Find | Pt | Bld/Tiss | Doc | FISH | 4p16.3 Del Bld/T FISH | |
| 2020-08-10 | 95553-4 | 5p15.2 (5p-) chromosome deletion [Identifier] in Blood or Tissue by FISH | 5p15.2 chromosome deletion | Prid | Pt | Bld/Tiss | Doc | FISH | 5p15.2 Del Bld/T FISH | |
| 2020-08-10 | 95551-8 | Chromosome region 17p11.2 deletion in Blood or Tissue by FISH | Chromosome region 17p11.2 deletion | Find | Pt | Bld/Tiss | Doc | FISH | Chr 17p11.2 Del Bld/T FISH | |
| 2020-08-10 | 95555-9 | F7 gene p.Arg353Gln [Genotype] in Blood or Tissue by Molecular genetics method Nominal | F7 gene.p.Arg353Gln | Geno | Pt | Bld/Tiss | Nom | Molgen | F7 R353Q Geno Bld/T | |
| 2020-08-10 | 95554-2 | Pancreatic exocrine cell Ab [Presence] in Serum by Immunofluorescence | Pancreatic exocrine cell Ab | PrThr | Pt | Ser | Ord | IF | Pancreatic exocrine cell Ab Ser Ql IF | |
| 2020-08-10 | 95556-7 | Adrenal cancer risk assessment and urine steroid fractions panel | Adrenal cancer risk assessment & urine steroid fractions panel | - | - | ^Patient | - | Adrenal ca risk assess+ur steroid Pnl | ||
| 2020-08-10 | 95557-5 | Detection basis of Tumor | Detection basis | Type | Pt | Tumor | Nom | Detection basis Tumor | ||
| 2020-08-10 | 95559-1 | Evidence of adrenal cortical hormone excess [Presence] in 24 hour Urine | Evidence of adrenal cortical hormone excess | PrThr | 24H | Urine | Ord | Adrenal hormone excess 24h Ur Ql | ||
| 2020-08-10 | 95560-9 | Androsterone [Z-score] in 24 hour Urine | Androsterone | Zscore | 24H | Urine | Qn | Androsterone 24h Z-score Ur | ||
| 2020-08-10 | 95558-3 | CT attenuation of adrenal mass | CT attenuation of mass | Rden | Pt | Abdomen>Adrenal gland | Qn | CT | CT attenuation of adrenal mass | |
| 2020-08-10 | 95561-7 | Etiocholanolone [Z-score] in 24 hour Urine | Etiocholanolone | Zscore | 24H | Urine | Qn | Etiocholanolone 24h Z-score Ur | ||
| 2020-08-10 | 95562-5 | Dehydroepiandrosterone (DHEA) [Z-score] in 24 hour Urine | Dehydroepiandrosterone | Zscore | 24H | Urine | Qn | DHEA 24h Z-score Ur | ||
| 2020-08-10 | 95563-3 | 16-Alpha hydroxydehydroepiandrosterone [Mass/time] in 24 hour Urine | 16-Alpha hydroxydehydroepiandrosterone | MRat | 24H | Urine | Qn | 16A OH-DHEA 24h Ur-mRate | ||
| 2020-08-10 | 95564-1 | 16-Alpha hydroxydehydroepiandrosterone [Z-score] in 24 hour Urine | 16-Alpha hydroxydehydroepiandrosterone | Zscore | 24H | Urine | Qn | 16A OH-DHEA 24h Z-score Ur | ||
| 2020-08-10 | 95565-8 | 5-Pregnenetriol [Mass/time] in 24 hour Urine | 5-Pregnenetriol | MRat | 24H | Urine | Qn | 5-Pregnenetriol 24h Ur-mRate | ||
| 2020-08-10 | 95566-6 | 5-Pregnenetriol [Z-score] in 24 hour Urine | 5-Pregnenetriol | Zscore | 24H | Urine | Qn | 5-Pregnenetriol 24h Z-score Ur | ||
| 2020-08-10 | 95567-4 | 5-Pregnenediol [Mass/time] in 24 hour Urine | 5-Pregnenediol | MRat | 24H | Urine | Qn | 5-Pregnenediol 24h Ur-mRate | ||
| 2020-08-10 | 95568-2 | 5-Pregnenediol [Z-score] in 24 hour Urine | 5-Pregnenediol | Zscore | 24H | Urine | Qn | 5-Pregnenediol 24h Z-score Ur | ||
| 2020-08-10 | 95569-0 | Tetrahydro-11-corticosterone [Mass/time] in 24 hour Urine | Tetrahydro-11-corticosterone | MRat | 24H | Urine | Qn | TH-11-corticosterone 24h Ur-mRate | ||
| 2020-08-10 | 95570-8 | Tetrahydro-11-corticosterone [Z-score] in 24 hour Urine | Tetrahydro-11-corticosterone | Zscore | 24H | Urine | Qn | TH-11-corticosterone 24h Z-score Ur | ||
| 2020-08-10 | 95571-6 | 11-Deoxytetrahydrocorticosterone [Mass/time] in 24 hour Urine | 11-Deoxytetrahydrocorticosterone | MRat | 24H | Urine | Qn | TH-DOC 24h Ur-mRate | ||
| 2020-08-10 | 95572-4 | 11-Deoxytetrahydrocorticosterone [Z-score] in 24 hour Urine | 11-Deoxytetrahydrocorticosterone | Zscore | 24H | Urine | Qn | TH-DOC 24h Z-score Ur | ||
| 2020-08-10 | 95573-2 | Pregnanediol [Z-score] in 24 hour Urine | Pregnanediol | Zscore | 24H | Urine | Qn | Pregnanediol 24h Z-score Ur | ||
| 2020-08-10 | 95575-7 | 17 Alpha-hydroxypregnanolone [Z-score] in 24 hour Urine | 17 alpha-Hydroxypregnanolone | Zscore | 24H | Urine | Qn | 17A-OH-pregnanolone 24h Z-score Ur | ||
| 2020-08-10 | 95576-5 | Pregnanetriol [Z-score] in 24 hour Urine | Pregnanetriol | Zscore | 24H | Urine | Qn | Pregntrl 24h Z-score Ur | ||
| 2020-08-10 | 95574-0 | 17 Alpha-hydroxypregnanolone [Mass/time] in 24 hour Urine | 17 alpha-Hydroxypregnanolone | MRat | 24H | Urine | Qn | 17A-OH-pregnanolone 24h Ur-mRate | ||
| 2020-08-10 | 95577-3 | Pregnanetriolone [Z-score] in 24 hour Urine | Pregnanetriolone | Zscore | 24H | Urine | Qn | Pregntrlone 24h Z-score Ur | ||
| 2020-08-10 | 95578-1 | Tetrahydrodeoxycortisol [Z-score] in 24 hour Urine | Tetrahydrodeoxycortisol | Zscore | 24H | Urine | Qn | TH-DC 24h Z-score Ur | ||
| 2020-08-10 | 95579-9 | Cortisol [Z-score] in 24 hour Urine | Cortisol | Zscore | 24H | Urine | Qn | Cortis 24h Z-score Ur | ||
| 2020-08-10 | 95580-7 | 6-Beta-Hydroxycortisol [Z-score] in 24 hour Urine | 6-Beta-Hydroxycortisol | Zscore | 24H | Urine | Qn | 6B-OH-Cortisol 24h Z-score Ur | ||
| 2020-08-10 | 95581-5 | Tetrahydrocortisol [Z-score] in 24 hour Urine | Tetrahydrocortisol | Zscore | 24H | Urine | Qn | THF 24h Z-score Ur | ||
| 2020-08-10 | 95582-3 | 5-Alpha tetrahydrocortisol [Z-score] in 24 hour Urine | 5-Alpha tetrahydrocortisol | Zscore | 24H | Urine | Qn | 5-A THF 24h Z-score Ur | ||
| 2020-08-10 | 95583-1 | Beta cortol [Z-score] in 24 hour Urine | Beta cortol | Zscore | 24H | Urine | Qn | Beta cortol 24h Z-score Ur | ||
| 2020-08-10 | 95584-9 | 11-Hydroxyandrosterone [Z-score] in 24 hour Urine | 11-Hydroxyandrosterone | Zscore | 24H | Urine | Qn | 11OH-Androst 24h Z-score Ur | ||
| 2020-08-10 | 95586-4 | Cortisone [Z-score] in 24 hour Urine | Cortisone | Zscore | 24H | Urine | Qn | Cortisone 24h Z-score Ur | ||
| 2020-08-10 | 95587-2 | Tetrahydrocortisone [Z-score] in 24 hour Urine | Tetrahydrocortisone | Zscore | 24H | Urine | Qn | THcortisone 24h Z-score Ur | ||
| 2020-08-10 | 95585-6 | 11-Hydroxyetiocholanolone [Z-score] in 24 hour Urine | 11-Hydroxyetiocholanolone | Zscore | 24H | Urine | Qn | 11OH-Etioch 24h Z-score Ur | ||
| 2020-08-10 | 95589-8 | Beta cortolone [Mass/time] in 24 hour Urine | Beta cortolone | MRat | 24H | Urine | Qn | B-cortolone 24h Ur-mRate | ||
| 2020-08-10 | 95590-6 | Beta cortolone [Z-score] in 24 hour Urine | Beta cortolone | Zscore | 24H | Urine | Qn | B-cortolone 24h Z-score Ur | ||
| 2020-08-10 | 95588-0 | Alpha cortolone [Z-score] in 24 hour Urine | Alpha cortolone | Zscore | 24H | Urine | Qn | A-cortolone 24h Z-score Ur | ||
| 2020-08-10 | 95591-4 | 11-Ketoetiocholanolone [Z-score] in 24 hour Urine | 11-Ketoetiocholanolone | Zscore | 24H | Urine | Qn | 11Ketoetioch 24h Z-score Ur | ||
| 2020-08-07 | 95532-8 | Human papilloma virus high-risk genotypes panel - Cervix by NAA with probe detection | Human papilloma virus high-risk genotypes panel | - | Pt | Cvx | - | Probe.amp.tar | HPV HR genotypes Pnl Cvx NAA+probe | |
| 2020-08-07 | 95533-6 | Human papilloma virus 56+59+66 DNA [Presence] in Cervix by NAA with probe detection | Human papilloma virus 56+59+66 DNA | PrThr | Pt | Cvx | Ord | Probe.amp.tar | HPV56+59+66 DNA Cvx Ql NAA+probe | |
| 2020-08-07 | 95534-4 | Human papilloma virus 52 DNA [Presence] in Cervix by NAA with probe detection | Human papilloma virus 52 DNA | PrThr | Pt | Cvx | Ord | Probe.amp.tar | HPV52 DNA Cvx Ql NAA+probe | |
| 2020-08-07 | 95535-1 | Human papilloma virus 51 DNA [Presence] in Cervix by NAA with probe detection | Human papilloma virus 51 DNA | PrThr | Pt | Cvx | Ord | Probe.amp.tar | HPV51 DNA Cvx Ql NAA+probe | |
| 2020-08-07 | 95536-9 | Human papilloma virus 45 DNA [Presence] in Cervix by NAA with probe detection | Human papilloma virus 45 DNA | PrThr | Pt | Cvx | Ord | Probe.amp.tar | HPV45 DNA Cvx Ql NAA+probe | |
| 2020-08-07 | 95537-7 | Human papilloma virus 35+39+68 DNA [Presence] in Cervix by NAA with probe detection | Human papilloma virus 35+39+68 DNA | PrThr | Pt | Cvx | Ord | Probe.amp.tar | HPV35+39+68 DNA Cvx Ql NAA+probe | |
| 2020-08-07 | 95538-5 | Human papilloma virus 33+58 DNA [Presence] in Cervix by NAA with probe detection | Human papilloma virus 33+58 DNA | PrThr | Pt | Cvx | Ord | Probe.amp.tar | HPV33+58 DNA Cvx Ql NAA+probe | |
| 2020-08-07 | 95540-1 | Carbapenem resistance blaIMP+blaVIM genes [Presence] by Molecular method | Bacterial carbapenem resistance blaIMP+blaVIM genes | PrThr | Pt | Isolate/Specimen | Ord | Molgen | blaIMP+blaVIM Islt/Spm Ql | |
| 2020-08-07 | 95539-3 | Human papilloma virus 31 DNA [Presence] in Cervix by NAA with probe detection | Human papilloma virus 31 DNA | PrThr | Pt | Cvx | Ord | Probe.amp.tar | HPV31 DNA Cvx Ql NAA+probe | |
| 2020-08-07 | 95541-9 | Care experience preference | Care experience preference | Find | Pt | ^Patient | Nom | Care experience preference | ||
| 2020-08-05 | 95528-6 | NIDA Quick Screen [NIDA] | NIDA Quick Screen | - | 1Y | ^Patient | - | NIDA | NIDA Quick Screen | |
| 2020-08-05 | 95529-4 | Tobacco use in the past year | Tobacco use in the past 1Y | Find | 1Y | ^Patient | Ord | Tobacco use 1Y | ||
| 2020-08-05 | 95531-0 | Illegal drug use in the past year | Illegal drug use in the past 1Y | Find | 1Y | ^Patient | Ord | Illegal drug use 1Y | ||
| 2020-08-05 | 95530-2 | Prescription drug use for non-medical reasons in the past year | Prescription drug use for non-medical reasons in the past 1Y | Find | 1Y | ^Patient | Ord | Prescription drug use 1Y | ||
| 2020-08-04 | 95523-7 | HIV 1 and 2 Ab panel - Serum or Plasma by Immunoassay | HIV 1 & 2 Ab panel | - | Pt | Ser/Plas | - | IA | HIV 1 + 2 Ab Pnl SerPl IA | |
| 2020-08-04 | 95524-5 | HIV 1 and 2 Ab [Identifier] in Serum or Plasma by Immunoassay | HIV 1 & 2 Ab | Prid | Pt | Ser/Plas | Nom | IA | HIV 1 & 2 Ab SerPl IA | |
| 2020-08-04 | 95525-2 | Chromium and cobalt panel [Mass/volume] - Synovial fluid | Chromium & cobalt panel | MCnc | Pt | Synv fld | Qn | Chromium + cobalt pnl Snv-mCnc | ||
| 2020-08-04 | 95526-0 | Chromium [Mass/volume] in Synovial fluid | Chromium | MCnc | Pt | Synv fld | Qn | Chromium Snv-mCnc | ||
| 2020-08-04 | 95527-8 | Cytomegalovirus IgG Ab [Presence] in Saliva (oral fluid) by Immunoassay | Cytomegalovirus Ab.IgG | PrThr | Pt | Saliva | Ord | IA | CMV IgG Sal Ql IA | |
| 2020-07-23 | 95520-3 | Integrative medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Integrative medicine | Integrative medicine Telehealth Note | |
| 2020-07-20 | 95514-6 | Keratometer Refractive index | Refractive index | InvLen | Pt | Keratometer | Qn | Keratometer Refract Indx | ||
| 2020-07-20 | 95515-3 | Angiotensin II (1-8) and angiotensin (1-7) panel - Plasma | Angiotensin II & angiotensin (1-7) panel | - | Pt | Plas | Qn | Ang II and Ang-(1-7) Pnl Plas | ||
| 2020-07-20 | 95516-1 | Angiotensin (1-7) [Mass/volume] in Plasma | Angiotensin (1-7) | MCnc | Pt | Plas | Qn | Ang-(1-7) Plas-mCnc | ||
| 2020-07-19 | 95430-5 | During the past 3 months, how often have you used cannabis | During the past 3Mo, how often have you used cannabis | Find | 3Mo | ^Patient | Ord | |||
| 2020-07-19 | 95431-3 | During the past 3 months, how often have you used cocaine | During the past 3Mo, how often have you used cocaine | Find | 3Mo | ^Patient | Ord | |||
| 2020-07-19 | 95432-1 | During the past 3 months, how often have you used prescription stimulants | During the past 3Mo, how often have you used prescription stimulants | Find | 3Mo | ^Patient | Ord | |||
| 2020-07-19 | 95433-9 | During the past 3 months, how often have you used methamphetamine | During the past 3Mo, how often have you used methamphetamine | Find | 3Mo | ^Patient | Ord | |||
| 2020-07-19 | 95434-7 | During the past 3 months, how often have you used inhalants | During the past 3Mo, how often have you used inhalants | Find | 3Mo | ^Patient | Ord | |||
| 2020-07-19 | 95436-2 | During the past 3 months, how often have you used hallucinogens | During the past 3Mo, how often have you used hallucinogens | Find | 3Mo | ^Patient | Ord | |||
| 2020-07-19 | 95435-4 | During the past 3 months, how often have you used sedatives or sleeping pills | During the past 3Mo, how often have you used sedatives or sleeping pills | Find | 3Mo | ^Patient | Ord | |||
| 2020-07-19 | 95438-8 | During the past 3 months, how often have you used prescription opioids | During the past 3Mo, how often have you used prescription opioids | Find | 3Mo | ^Patient | Ord | |||
| 2020-07-19 | 95437-0 | During the past 3 months, how often have you used street opioids | During the past 3Mo, how often have you used street opioids | Find | 3Mo | ^Patient | Ord | |||
| 2020-07-19 | 95439-6 | During the past 3 months, how often have you used other substances [NIDA] | During the past 3Mo, how often have you used other substances | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95440-4 | During the past 3 months, how often have you had a strong desire or urge to use cannabis [NIDA] | During the past 3Mo, how often have you had a strong desire or urge to use cannabis | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95441-2 | During the past 3 months, how often have you had a strong desire or urge to use cocaine [NIDA] | During the past 3Mo, how often have you had a strong desire or urge to use cocaine | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95442-0 | During the past 3 months, how often have you had a strong desire or urge to use prescription stimulants [NIDA] | During the past 3Mo, how often have you had a strong desire or urge to use prescription stimulants | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95443-8 | During the past 3 months, how often have you had a strong desire or urge to use methamphetamine [NIDA] | During the past 3Mo, how often have you had a strong desire or urge to use methamphetamine | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95444-6 | During the past 3 months, how often have you had a strong desire or urge to use inhalants [NIDA] | During the past 3Mo, how often have you had a strong desire or urge to use inhalants | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95445-3 | During the past 3 months, how often have you had a strong desire or urge to use sedatives or sleeping pills [NIDA] | During the past 3Mo, how often have you had a strong desire or urge to use sedatives or sleeping pills | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95446-1 | During the past 3 months, how often have you had a strong desire or urge to use hallucinogens [NIDA] | During the past 3Mo, how often have you had a strong desire or urge to use hallucinogens | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95447-9 | During the past 3 months, how often have you had a strong desire or urge to use street opioids [NIDA] | During the past 3Mo, how often have you had a strong desire or urge to use street opioids | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95448-7 | During the past 3 months, how often have you had a strong desire or urge to use prescription opioids [NIDA] | During the past 3Mo, how often have you had a strong desire or urge to use prescription opioids | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95449-5 | During the past 3 months, how often have you had a strong desire or urge to use other substances [NIDA] | During the past 3Mo, how often have you had a strong desire or urge to use other substances | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95450-3 | During the past 3 months, how often has your use of cannabis led to health, social, legal or financial problems [NIDA] | During the past 3Mo, how often has your use of cannabis led to health, social, legal or financial problems | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95451-1 | During the past 3 months, how often has your use of cocaine led to health, social, legal or financial problems [NIDA] | During the past 3Mo, how often has your use of cocaine led to health, social, legal or financial problems | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95452-9 | During the past 3 months, how often has your use of prescription stimulants led to health, social, legal or financial problems [NIDA] | During the past 3Mo, how often has your use of prescription stimulants led to health, social, legal or financial problems | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95453-7 | During the past 3 months, how often has your use of methamphetamine led to health, social, legal or financial problems [NIDA] | During the past 3Mo, how often has your use of methamphetamine led to health, social, legal or financial problems | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95454-5 | During the past 3 months, how often has your use of inhalants led to health, social, legal or financial problems [NIDA] | During the past 3Mo, how often has your use of inhalants led to health, social, legal or financial problems | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95455-2 | During the past 3 months, how often has your use of sedatives or sleeping pills led to health, social, legal or financial problems [NIDA] | During the past 3Mo, how often has your use of sedatives or sleeping pills led to health, social, legal or financial problems | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95456-0 | During the past 3 months, how often has your use of hallucinogens led to health, social, legal or financial problems [NIDA] | During the past 3Mo, how often has your use of hallucinogens led to health, social, legal or financial problems | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95457-8 | During the past 3 months, how often has your use of street opioids led to health, social, legal or financial problems [NIDA] | During the past 3Mo, how often has your use of street opioids led to health, social, legal or financial problems | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95459-4 | During the past 3 months, how often has your use of other substances led to health, social, legal or financial problems [NIDA] | During the past 3Mo, how often has your use of other substances led to health, social, legal or financial problems | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95458-6 | During the past 3 months, how often has your use of prescription opioids led to health, social, legal or financial problems [NIDA] | During the past 3Mo, how often has your use of prescription opioids led to health, social, legal or financial problems | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95460-2 | During the past 3 months, how often have you failed to do what was normally expected of you because of your use of cannabis [NIDA] | During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of cannabis | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95461-0 | During the past 3 months, how often have you failed to do what was normally expected of you because of your use of cocaine [NIDA] | During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of cocaine | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95462-8 | During the past 3 months, how often have you failed to do what was normally expected of you because of your use of prescribed Amphetamine type stimulants [NIDA] | During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of prescribed Amphetamine type stimulants | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95463-6 | During the past 3 months, how often have you failed to do what was normally expected of you because of your use of methamphetamine [NIDA] | During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of methamphetamine | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95464-4 | During the past 3 months, how often have you failed to do what was normally expected of you because of your use of inhalants [NIDA] | During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of inhalants | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95465-1 | During the past 3 months, how often have you failed to do what was normally expected of you because of your use of sedatives or sleeping pills [NIDA] | During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of sedatives or sleeping pills | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95466-9 | During the past 3 months, how often have you failed to do what was normally expected of you because of your use of hallucinogens [NIDA] | During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of hallucinogens | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95467-7 | During the past 3 months, how often have you failed to do what was normally expected of you because of your use of street opioids [NIDA] | During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of street opioids | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95468-5 | During the past 3 months, how often have you failed to do what was normally expected of you because of your use of prescription opioids [NIDA] | During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of prescription opioids | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95469-3 | During the past 3 months, how often have you failed to do what was normally expected of you because of your use of other substances [NIDA] | During the past 3Mo, how often have you failed to do what was normally expected of you because of your use of other substances | Find | 3Mo | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95470-1 | Has a friend or relative or anyone else ever expressed concern about your use of cannabis [NIDA] | Has a friend or relative or anyone else ever expressed concern about your use of cannabis | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95471-9 | Has a friend or relative or anyone else ever expressed concern about your use of cocaine [NIDA] | Has a friend or relative or anyone else ever expressed concern about your use of cocaine | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95472-7 | Has a friend or relative or anyone else ever expressed concern about your use of prescribed Amphetamine type stimulants [NIDA] | Has a friend or relative or anyone else ever expressed concern about your use of prescribed Amphetamine type stimulants | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95473-5 | Has a friend or relative or anyone else ever expressed concern about your use of methamphetamine [NIDA] | Has a friend or relative or anyone else ever expressed concern about your use of methamphetamine | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95474-3 | Has a friend or relative or anyone else ever expressed concern about your use of inhalants [NIDA] | Has a friend or relative or anyone else ever expressed concern about your use of inhalants | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95475-0 | Has a friend or relative or anyone else ever expressed concern about your use of sedatives or sleeping pills [NIDA] | Has a friend or relative or anyone else ever expressed concern about your use of sedatives or sleeping pills | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95476-8 | Has a friend or relative or anyone else ever expressed concern about your use of hallucinogens [NIDA] | Has a friend or relative or anyone else ever expressed concern about your use of hallucinogens | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95477-6 | Has a friend or relative or anyone else ever expressed concern about your use of street opioids [NIDA] | Has a friend or relative or anyone else ever expressed concern about your use of street opioids | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95478-4 | Has a friend or relative or anyone else ever expressed concern about your use of prescription opioids [NIDA] | Has a friend or relative or anyone else ever expressed concern about your use of prescription opioids | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95480-0 | Other substances that have caused a friend or relative or anyone else to ever express concern about your use of other substances [NIDA] | Other substances that have caused a friend or relative or anyone else to ever express concern about your use of other substances | - | Pt | ^Patient | - | NIDA | ||
| 2020-07-19 | 95479-2 | Has a friend or relative or anyone else ever expressed concern about your use of other substances [NIDA] | Has a friend or relative or anyone else ever expressed concern about your use of other substances | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95481-8 | Substances that have caused a friend or relative or anyone else to ever express concern about your use [NIDA] | Substances that have caused a friend or relative or anyone else to ever express concern about your use | Type | Pt | ^Patient | Nom | NIDA | ||
| 2020-07-19 | 95482-6 | Have you ever tried and failed to control, cut down or stop using cannabis [NIDA] | Have you ever tried and failed to control, cut down or stop using cannabis | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95483-4 | Have you ever tried and failed to control, cut down or stop using cocaine [NIDA] | Have you ever tried and failed to control, cut down or stop using cocaine | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95484-2 | Have you ever tried and failed to control, cut down or stop using prescribed Amphetamine type stimulants [NIDA] | Have you ever tried and failed to control, cut down or stop using prescribed Amphetamine type stimulants | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95485-9 | Have you ever tried and failed to control, cut down or stop using methamphetamine [NIDA] | Have you ever tried and failed to control, cut down or stop using methamphetamine | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95486-7 | Have you ever tried and failed to control, cut down or stop using inhalants [NIDA] | Have you ever tried and failed to control, cut down or stop using inhalants | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95487-5 | Have you ever tried and failed to control, cut down or stop using sedatives or sleeping pills [NIDA] | Have you ever tried and failed to control, cut down or stop using sedatives or sleeping pills | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95488-3 | Have you ever tried and failed to control, cut down or stop using hallucinogens [NIDA] | Have you ever tried and failed to control, cut down or stop using hallucinogens | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95489-1 | Have you ever tried and failed to control, cut down or stop using street opioids [NIDA] | Have you ever tried and failed to control, cut down or stop using street opioids | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95490-9 | Have you ever tried and failed to control, cut down or stop using prescription opioids [NIDA] | Have you ever tried and failed to control, cut down or stop using prescription opioids | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95492-5 | Injection drug use Lifetime | Injection drug use | Find | Lifetime | ^Patient | Ord | Injection drug use Lifetime | ||
| 2020-07-19 | 95491-7 | Have you ever tried and failed to control, cut down or stop using other substances [NIDA] | Have you ever tried and failed to control, cut down or stop using other substances | Find | Pt | ^Patient | Ord | NIDA | ||
| 2020-07-19 | 95494-1 | Substances used during the past 3 months | Substances used during the past 3Mo | Type | Pt | ^Patient | Nom | Substances used past 3Mo | ||
| 2020-07-19 | 95493-3 | Cannabis substance involvement score [NIDA] | Cannabis substance involvement score | Score | Pt | ^Patient | Qn | NIDA | ||
| 2020-07-19 | 95495-8 | Other substances used during the past 3 months [NIDA] | Other substances used during the past 3Mo | - | 3Mo | ^Patient | - | NIDA | ||
| 2020-07-19 | 95496-6 | Other substances that you have had a strong desire or urge to use in the past 3 months [NIDA] | Other substances that you have had a strong desire or urge to use in the past 3Mo | - | 3Mo | ^Patient | - | NIDA | ||
| 2020-07-19 | 95497-4 | Other substances that have led to health, social, legal or financial problems in the past 3 months [NIDA] | Other substances that have led to health, social, legal or financial problems in the past 3Mo | - | 3Mo | ^Patient | - | NIDA | ||
| 2020-07-19 | 95498-2 | Other substances that have caused you to fail to do what was normally expected of you in the past 3 months [NIDA] | Other substances that have caused you to fail to do what was normally expected of you in the past 3Mo | - | 3Mo | ^Patient | - | NIDA | ||
| 2020-07-19 | 95499-0 | Other substances that you have ever tried and failed to control, cut down or stop using [NIDA] | Other substances that you have ever tried and failed to control, cut down or stop using | - | Pt | ^Patient | - | NIDA | ||
| 2020-07-19 | 95500-5 | Substances you have had a strong desire or urge to use during the past 3 months [NIDA] | Substances you have had a strong desire or urge to use during the past 3Mo | Type | 3Mo | ^Patient | Nom | NIDA | ||
| 2020-07-19 | 95501-3 | Substances that have led to health, social, legal or financial problems during the past 3 months [NIDA] | Substances that have led to health, social, legal or financial problems during the past 3Mo | Type | 3Mo | ^Patient | Nom | NIDA | ||
| 2020-07-19 | 95502-1 | Substances that have caused you to fail to do what was normally expected of you during the past 3 months [NIDA] | Substances that have caused you to fail to do what was normally expected of you during the past 3Mo | Type | 3Mo | ^Patient | Nom | NIDA | ||
| 2020-07-19 | 95503-9 | Substances that you have ever tried and failed to control, cut down or stop using [NIDA] | Substances that you have ever tried and failed to control, cut down or stop using | Type | Pt | ^Patient | Nom | NIDA | ||
| 2020-07-19 | 95504-7 | Cocaine substance involvement score [NIDA] | Cocaine substance involvement score | Score | Pt | ^Patient | Qn | NIDA | ||
| 2020-07-19 | 95505-4 | Prescription stimulants substance involvement score [NIDA] | Prescription stimulants substance involvement score | Score | Pt | ^Patient | Qn | NIDA | ||
| 2020-07-19 | 95506-2 | Methamphetamine substance involvement score [NIDA] | Methamphetamine substance involvement score | Score | Pt | ^Patient | Qn | NIDA | ||
| 2020-07-19 | 95507-0 | Inhalants substance involvement score [NIDA] | Inhalants substance involvement score | Score | Pt | ^Patient | Qn | NIDA | ||
| 2020-07-19 | 95508-8 | Sedatives or sleeping pills substance involvement score [NIDA] | Sedatives or sleeping pills substance involvement score | Score | Pt | ^Patient | Qn | NIDA | ||
| 2020-07-19 | 95509-6 | Hallucinogens substance involvement score [NIDA] | Hallucinogens substance involvement score | Score | Pt | ^Patient | Qn | NIDA | ||
| 2020-07-19 | 95510-4 | Street opioids substance involvement score [NIDA] | Street opioids substance involvement score | Score | Pt | ^Patient | Qn | NIDA | ||
| 2020-07-19 | 95511-2 | Prescription opioids substance involvement score [NIDA] | Prescription opioids substance involvement score | Score | Pt | ^Patient | Qn | NIDA | ||
| 2020-07-19 | 95512-0 | Other substance involvement score [NIDA] | Other substance involvement score | Score | Pt | ^Patient | Qn | NIDA | ||
| 2020-07-19 | 95513-8 | NIDA-Modified ASSIST version 2.0 [NIDA] | NIDA-Modified ASSIST version 2.0 | - | Pt | ^Patient | - | NIDA | ||
| 2020-07-01 | 95426-3 | Level of independence | Level of independence | Type | Pt | ^Patient | Nom | Level of independence | ||
| 2016-11-17 | 83114-9 | S100 calcium binding protein B [Mass/volume] in Serum by Immunoassay | S100 calcium binding protein B | MCnc | Pt | Ser | Qn | IA | S100 Ca binding protein B Ser IA-mCnc |
TIP Click on headings to sort table by that column. Hold down Shift and click additional headings to add to sorting.
TIP In your web browser, use ControlF (or ⌘F on Mac) to find text on this page.
Receive notices of new and revised Special Use prerelease codes
Sign up to receive an email notification when new prerelease Special Use LOINC terms are created or revised.
For timely updates, follow @LOINC on Twitter. An RSS feed of new Special Use terms is also available.